{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:14:45Z","timestamp":1758046485456,"version":"3.44.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T00:00:00Z","timestamp":1732406400000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ando.2023.04.003","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T19:20:35Z","timestamp":1682104835000},"page":"773-778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic choices in elderly diabetic patients"],"prefix":"10.1016","volume":"84","author":[{"given":"Lyse","family":"Bordier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Doucet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Bauduceau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2023.04.003_bib0255","article-title":"Diab\u00e8te des personnes \u00e2g\u00e9es","author":"Bordier","year":"2017","journal-title":"EMC\u00a0\u2013\u00a0Endocrinologie\u00a0\u2013\u00a0Nutrition"},{"year":"2013","series-title":"Recommandation de bonne pratique de la Haute Autorit\u00e9 de sant\u00e9 (HAS). Strat\u00e9gie m\u00e9dicamenteuse du contr\u00f4le glyc\u00e9mique du diab\u00e8te de type 2","author":"HAS","key":"10.1016\/j.ando.2023.04.003_bib0260"},{"key":"10.1016\/j.ando.2023.04.003_bib0265","unstructured":"Le diab\u00e8te en France\u00a0: les chiffres 2020. Sant\u00e9 publique France https:\/\/www.santepubliquefrance.fr\/."},{"year":"2018","series-title":"Le poids du diab\u00e8te en France en 2016. Synth\u00e8se \u00e9pid\u00e9miologique","author":"Fosse-Edorh","key":"10.1016\/j.ando.2023.04.003_bib0270"},{"year":"2013","series-title":"Comment rep\u00e9rer la fragilit\u00e9 en soins ambulatoires\u00a0?","author":"HAS","key":"10.1016\/j.ando.2023.04.003_bib0275"},{"key":"10.1016\/j.ando.2023.04.003_bib0280","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype. Cardiovascular Health Study Collaborative Research Group","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci Med Sci"},{"key":"10.1016\/j.ando.2023.04.003_bib0285","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1503\/cmaj.050051","article-title":"A global clinical measure of fitness and frailty in elderly people","volume":"173","author":"Rockwood","year":"2005","journal-title":"CMAJ"},{"year":"2021","series-title":"Diagnostic de la d\u00e9nutrition chez la personne de 70\u00a0ans et plus","author":"HAS","key":"10.1016\/j.ando.2023.04.003_bib0290"},{"key":"10.1016\/j.ando.2023.04.003_bib0295","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ageing\/afz046","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"10.1016\/j.ando.2023.04.003_bib0300","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1007\/s00125-005-0023-4","article-title":"Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies","volume":"48","author":"Cukierman","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2023.04.003_bib0305","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/jdi.12087","article-title":"Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies","volume":"4","author":"Gudala","year":"2013","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.ando.2023.04.003_bib0310","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1176\/appi.ajp.2014.14070878","article-title":"Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis","volume":"172","author":"Cooper","year":"2015","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.ando.2023.04.003_bib0315","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.diabet.2012.07.001","article-title":"GERODIAB: Glycaemic control and 5-year morbidity\/mortality of type 2 diabetic patients aged 70 years and older: 1. Description of the population at inclusion","volume":"38","author":"Doucet","year":"2012","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ando.2023.04.003_bib0320","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2337\/dc17-1437","article-title":"Cardiovascular complications over 5 years and their association with survival in the GERODIAB Cohort of Elderly French patients with type 2 diabetes","volume":"41","author":"Bauduceau","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2023.04.003_bib0325","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cger.2014.08.022","article-title":"Depression among older adults with diabetes mellitus","volume":"31","author":"Park","year":"2015","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.ando.2023.04.003_bib0330","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jdiacomp.2018.04.007","article-title":"Recurrent hospitalizations for severe hypoglycemia and hyperglycemia among US adults with diabetes","volume":"32","author":"McCoy","year":"2018","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.ando.2023.04.003_bib0335","doi-asserted-by":"crossref","first-page":"571568","DOI":"10.3389\/fendo.2021.571568","article-title":"Meta-analysis: association between hypoglycemia and serious adverse events in older patients treated with glucose-lowering agents","volume":"12","author":"Mattishent","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ando.2023.04.003_bib0340","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00125-020-05223-3","article-title":"Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study","volume":"63","author":"Zaccardi","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2023.04.003_bib0345","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1080\/14656566.2021.1912735","article-title":"Careful use to minimize adverse events of oral antidiabetic medications in the elderly","volume":"22","author":"Scheen","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ando.2023.04.003_bib0350","series-title":"Diab\u00e9tologie","first-page":"91","article-title":"Mesures hygi\u00e9nodi\u00e9t\u00e9tiques et \u00e9tats diab\u00e9tiques","author":"Colette","year":"2014"},{"year":"2014","series-title":"Nutrition clinique pratique chez l\u2019adulte et l\u2019enfant","author":"Schlienger","key":"10.1016\/j.ando.2023.04.003_bib0355"},{"key":"10.1016\/j.ando.2023.04.003_bib0360","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1249\/MSS.0000000000000356","article-title":"Activity-related energy expenditure in older adults: a call for more research","volume":"46","author":"Hall","year":"2014","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.ando.2023.04.003_bib0365","first-page":"781","article-title":"Prise de position de la Soci\u00e9t\u00e9 francophone du diab\u00e8te (SFD) sur les strat\u00e9gies d\u2019utilisation des traitements anti-hyperglyc\u00e9miants dans le diab\u00e8te de type 2-2021","volume":"15","author":"Darmon","year":"2021","journal-title":"Med Mal Metab"},{"key":"10.1016\/j.ando.2023.04.003_bib0370","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc20-Sint","article-title":"Standards of medical care in diabetes-2020","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2023.04.003_bib0375","first-page":"201","article-title":"Faut-il d\u00e9pister la carence en vitamine B12\u00a0chez les patients diab\u00e9tiques trait\u00e9s par metformine\u00a0?","volume":"15","author":"Bordier","year":"2021","journal-title":"Med Mal Metab"},{"key":"10.1016\/j.ando.2023.04.003_bib0380","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Metformin use and mortality among patients with diabetes and atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ando.2023.04.003_bib0385","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.04.003_bib0390","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2337\/dc06-1789","article-title":"A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin","volume":"30","author":"Gangji","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2023.04.003_bib0395","doi-asserted-by":"crossref","first-page":"i3625","DOI":"10.1136\/bmj.i3625","article-title":"Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study","volume":"354","author":"Van Dalem","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ando.2023.04.003_bib0400","first-page":"1468","article-title":"S\u00e9curit\u00e9 cardiovasculaire des inhibiteurs de la DPP-4\u00a0compar\u00e9e \u00e0 celle des sulfamides","volume":"14","author":"Scheen","year":"2018","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.ando.2023.04.003_bib0405","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs. glimepiride on major adverse cardiovascular outcomes in patients with type 2 Diabetes: the CAROLINA Randomized Clinical Trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ando.2023.04.003_bib0410","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/dom.14254","article-title":"Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: a subgroup analysis of the randomized CAROLINA trial","volume":"23","author":"Espeland","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ando.2023.04.003_bib0415","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","article-title":"Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Holman","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2023.04.003_bib0420","first-page":"CD013650","article-title":"Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis","volume":"10","author":"Kanie","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ando.2023.04.003_bib0425","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.diabet.2017.05.013","article-title":"Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: a systematic review and meta-analysis","volume":"43","author":"Men","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ando.2023.04.003_bib0430","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1463-1326.2011.01493.x","article-title":"Achieving a clinically relevant composite outcome of an HbA1c of\u00a0<\u00a07% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme","volume":"14","author":"Zinman","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ando.2023.04.003_bib0435","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2023.04.003_bib0440","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.04.003_bib0445","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2023.04.003_bib0450","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jdi.12420","article-title":"Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus","volume":"7","author":"Groeneveld","year":"2016","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.ando.2023.04.003_bib0455","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.04.003_bib0460","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.04.003_bib0465","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.04.003_bib0470","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.04.003_bib0475","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ando.2023.04.003_bib0480","first-page":"293","article-title":"Les analogues lents de l\u2019insuline\u00a0: une aide pour l\u2019insulinoth\u00e9rapie des sujets \u00e2g\u00e9s","volume":"8","author":"Bauduceau","year":"2014","journal-title":"Med Mal Metab"},{"key":"10.1016\/j.ando.2023.04.003_bib0485","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2337\/dc18-0559","article-title":"More similarities than differences testing insulin glargine 300 units\/mL versus insulin degludec 100 units\/mL in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2023.04.003_bib0490","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/1932296819841585","article-title":"Efficacy and safety of degludec compared to glargine 300 units\/mL in insulin-experienced patients with type 2 diabetes: trial protocol amendment (NCT03078478)","volume":"13","author":"Philis-Tsimikas","year":"2019","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.ando.2023.04.003_bib0495","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00125-020-05370-7","article-title":"Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: a population-based study","volume":"64","author":"Lega","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2023.04.003_bib0500","first-page":"801","article-title":"Diab\u00e8te de type 2\u00a0de la personne \u00e2g\u00e9e. Vers des recommandations actualis\u00e9es\u00a0? L\u2019apport de la cohorte GERODIAB","volume":"15","author":"Doucet","year":"2021","journal-title":"Med Mal Metab"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000342662300080X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000342662300080X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:55:04Z","timestamp":1757717704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000342662300080X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S000342662300080X"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2023.04.003","relation":{},"ISSN":["0003-4266"],"issn-type":[{"type":"print","value":"0003-4266"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic choices in elderly diabetic patients","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2023.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}